Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics

International Journal of Epidemiology

Volumn 41, Issue 6, 2012, Pages 1807-1820

  May, Margaret T ^a   Hogg, Robert S ^b,c   Justice, Amy C ^d,e   Shepherd, Bryan E ^f   Costagliola, Dominique ^g,h,i   Ledergerber, Bruno ^j   Thiébaut, Rodolphe ^g,k   John Gill, M ^l   Kirk, Ole ^m,n   van Sighem, Ard ^o   Saag, Michael S ^p   Navarro, Gemma ^q   Sobrino Vegas, Paz ^r   Lampe, Fiona ^s   Ingle, Suzanne ^a   Guest, Jodie L ^t   Crane, Heidi M ^u   D'Arminio, Monforte Antonella ^v   Vehreschild, Jörg J ^w   Sterne, Jonathan A C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INSERM   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k UNIVERSITÉ DE BORDEAUX   (France)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ Rigshospitalet   (Denmark)

^o STICHTING HIV MONITORING   (Netherlands)

^p University of Alabama at Birmingham   (United States)

^q Infectious Diseases Program   (Spain)

^r CARLOS III INSTITUTE OF HEALTH   (Spain)

^s ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^t ATLANTA VA MEDICAL CENTER   (United States)

^u UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^v UNIVERSITY OF MILAN   (Italy)

^w UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

more..

Author keywords

AIDS; Antiretroviral therapy; Cohort; Heterogeneity; HIV; Mortality; Prognostic model; Socio economic status

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DISEASE TRANSMISSION; DISEASE TREATMENT; HEALTH POLICY; HEALTH RISK; HETEROGENEITY; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; NUMERICAL MODEL; RISK FACTOR; SOCIOECONOMIC STATUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DISEASE TRANSMISSION; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOCIAL STATUS; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; PROGNOSIS; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EUROPE; NORTH AMERICA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872125614     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dys164     Document Type: Article

References (52)

1. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospectivestudies. Lancet 2002;360:119-29.
2. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
3. Babiker A, Darbyshire J, Pezzotti P et al. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. J Acquir Immune Defic Syndr 2003;32: 303-10.
4. Sabin CA, Smith CJ, D'Arminio MA et al. Response to combination antiretroviral therapy: variation by age. AIDS 2008;22:1463-73.
5. Law M, Friis-Moller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003;4:1-10.
6. Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-24.
7. Lodwick RK, Sabin CA, Porter K et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010;376:340-45.
8. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-63.
9. May M, Sterne JA, Sabin C et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185-97.
10. Gras L, Kesselring AM, Griffin JT et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007;45:183-92.
11. Binquet C, Chene G, Jacqmin-Gadda H et al. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol 2001;153: 386-93.
12. Grabar S, Pradier C, Le CE et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000;14: 141-49.
13. Lundgren JD, Phillips AN, Vella S et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:153-60.
14. D'Arminio MA, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14: 499-507.
15. Fatkenheuer G, Theisen A, Rockstroh J et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11: F113-16.
16. Jaen A, Casabona J, Esteve A et al. [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc) 2005;124:525-31.
17. Sobrino-Vegas P, Gutierrez F, Berenguer J et al. La cohorte de la red española de investigación de VIH (CoRIS) y su asociado biobanco; cuestiones de organización, las principales conclusiones y pérdidas durante el seguimiento [The cohort of the Spanish HIV Research Network (coris) and its associated biobank; organizational issues, main findings and losses to follow-up]. Enferm Infecc Microbiol Clin 2011;29:645-53.
18. Lampe FC, Smith CJ, Madge S et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007;167:692-700.
19. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
20. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998;12:2161-67.
21. Schoeni-Affolter F, Ledergerber B, Rickenbach M et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010;39:1179-89.
22. Chen RY, Accortt NA, Westfall AO et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006;42:1003-10.
23. Fultz SL, Skanderson M, Mole LA et al. Development and verification of a "virtual"cohort using the National VA Health Information System. Med Care 2006;44 (8 Suppl 2):S25-30.
24. Justice AC, Dombrowski E, Conigliaro J et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006;44(8 Suppl 2):S13-24.
25. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004;39: 1507-13.
26. Lemly DC, Shepherd BE, Hulgan T et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009; 199:991-98.
27. Kitahata MM, Dillingham PW, Chaiyakunapruk N et al. Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort. Clin Infect Dis 2003;36:803-11.
28. Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. metan: fixed- and randomeffects meta-analysis. Stata J 2008;8:3-28.
29. DerSimonian R, Laird N. Meta-analysis in clinical-trials. Control Clin Trials 1986;7:177-88.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
31. Lewden C, Jougla E, Alioum A et al. Number of deaths among HIV-infected adults in France in 2000, threesource capture-recapture estimation. Epidemiol Infect 2006;134:1345-52.
32. Harris RJ, Sterne JA, Abgrall S et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008;13:959-67.
33. Justice AC, McGinnis KA, Skanderson M et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010;11: 143-51.
34. Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol 2009;62:729-37.
35. Lanoy E, Mary-Krause M, Tattevin P et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 2006;59:829-35.
36. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005"surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-98.
37. Centers for Disease Control and Prevention (CDC). Electronic record linkage to identify deaths among persons with AIDS: district of Columbia 2000-2005. MMWR Morb Mortal Wkly Rep 2008;57:631-34.
38. Hill T, Bansi L, Sabin C et al. Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol 2010;63:1101-09.
39. Schoni-Affolter F, Keiser O, Mwango A et al. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PLoS One 2011;6:e27919.
40. Lanoy E, Lewden C, Lievre L et al. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalite 2000 survey and death certificates. HIV Med 2009;10:236-45.
41. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009;4:e5790.
42. Brinkhof MW, Spycher BD, Yiannoutsos C et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One 2010;5: e14149.
43. Egger M, Spycher BD, Sidle J et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 2011;8:e1000390.
44. Public Health Agency of Canada. HIV/AIDS Epi Update 2010: Chapter 8 HIV/AIDS Among Aboriginal People in Canada. 2010. http://www.phac-aspc.gc.ca/aids-sida/publication/epi/2010/8-eng.php (10 August 2012, date last accessed).
45. Braithwaite RS, McGinnis KA, Conigliaro J et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005;29:1190-97.
46. World Health Organization. Global Health Indicators: Part 2. http://www.who.int/whosis/whostat/EN_WHS08_Table4_HSR.pdf (10 August 2012, date last accessed).
47. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from states, United States. J Acquir Immune Defic Syndr 2010; 53:124-30.
48. Wilkins R, Uppal S, Fines P, Senecal S, Guimond E, Dion R. Life expectancy in the Inuit-inhabited areas of Canada, 1989 to 2003. Health Rep 2008;19:1-13. Statistics Canada. http://www.statcan.gc.ca/pub/82-003-x/2008001/article/10463-eng.pdf (10 August 2012, date last accessed).
49. Joy R, Druyts EF, Brandson EK et al. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr 2008;47:500-05.
50. Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med 2009;68:1044-49.
51. Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health 2011;88:545-55.
52. Marrugat J, D'Agostino R, Sullivan L et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003;57:634-38.